“STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS”, ReFocus, vol. 2, no. 1, pp. 11–19, Feb. 2023, doi: 10.66073/researchfocus.v2i1.2819.